# Circulating IL-17A accumulation reflects effective target blockade with secukinumab in spondyloarthritis

## TL;DR

This study shows that increased IL-17A levels in patients treated with secukinumab are due to antibody-bound forms, which correlate with better treatment outcomes in spondyloarthritis.

## Contribution

The study introduces an IgG column-based assay to distinguish free and antibody-bound IL-17A, revealing its role as a biomarker for treatment efficacy.

## Key findings

- Serum IL-17A levels significantly increased after secukinumab treatment, mainly due to antibody-bound forms.
- Higher antibody-bound IL-17A levels correlated with improved clinical outcomes, as measured by ASDAS and CRP.
- The novel IgG column-based assay effectively separates free and bound cytokine forms, offering a new tool for monitoring treatment response.

## Abstract

To investigate the dynamics of IL-17A levels in patients with spondyloarthritis (SpA) treated with secukinumab and to determine the relationship between circulating IL-17A forms and clinical response.

We analyzed serum IL-17A levels in 33 samples from 11 SpA patients using the highly sensitive proximity extension assay (PEA) at baseline and after 6 and 12 months of secukinumab treatment. Clinical parameters including ASDAS and CRP were recorded. To distinguish free IL- 17A from secukinumab-bound IL-17A, we developed an innovative IgG column-based assay that separates free cytokine from antibody-conjugated fractions.

Serum IL-17A levels significantly increased at 6 and 12 months post-secukinumab treatment. This increase correlated negatively with ASDAS and CRP, indicating better clinical response. Analysis showed that the rise was mainly due to the secukinumab-bound IL-17A fraction, while free IL-17A levels remained stable.

Our study reveals that the elevated IL-17A levels detected after secukinumab treatment primarily represent the antibody-conjugated form rather than free cytokine. This conjugated fraction is associated with improved clinical outcomes, suggesting it could serve as a biomarker for therapeutic efficacy. The novel IgG column-based assay provides a valuable tool for differentiating cytokine forms in patients undergoing monoclonal antibody therapies, with potential applications beyond SpA. These findings advance understanding of IL-17A dynamics during treatment and open new avenues for personalized monitoring and management in autoimmune diseases.